MGMT-METHYLATED GLIOBLASTOMA
Clinical trials for MGMT-METHYLATED GLIOBLASTOMA explained in plain language.
Never miss a new study
Get alerted when new MGMT-METHYLATED GLIOBLASTOMA trials appear
Sign up with your email to follow new studies for MGMT-METHYLATED GLIOBLASTOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to outsmart recurrent glioblastoma
Disease control Recruiting nowThis study tests whether adding the drug selinexor to standard chemotherapy (temozolomide) can better control recurrent glioblastoma, an aggressive brain cancer. About 97 adults whose tumor has returned after initial treatment will receive either the combo or chemotherapy alone. …
Matched conditions: MGMT-METHYLATED GLIOBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Can a common white blood cell booster shield the brain from Chemo-Radiation damage?
Disease control Recruiting nowThis phase 2 pilot study tests whether granulocyte colony stimulating factor (G-CSF), a drug that boosts white blood cells, can help preserve brain structure and thinking skills in people with a specific type of glioblastoma (MGMT-methylated) undergoing standard chemoradiation. A…
Matched conditions: MGMT-METHYLATED GLIOBLASTOMA
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Promising combo therapy for aggressive brain cancer enters final testing phase
Disease control Recruiting nowThis Phase 3 trial tests whether adding lomustine to standard temozolomide chemotherapy improves survival for people with newly diagnosed glioblastoma that has a specific genetic marker (MGMT methylated). About 200 adults aged 18-70 will be randomly assigned to receive either the…
Matched conditions: MGMT-METHYLATED GLIOBLASTOMA
Phase: PHASE3 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for brain cancer: experimental virus therapy targets aggressive tumors
Disease control Recruiting nowThis study tests whether adding two experimental drugs, DB107-RRV and DB107-FC, to standard treatment (radiation and chemotherapy) can help people with newly diagnosed high grade glioma, a fast-growing brain cancer. About 70 adults aged 18-75 will receive the drugs during and aft…
Matched conditions: MGMT-METHYLATED GLIOBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Could a new combo therapy extend life in aggressive brain cancer?
Disease control Recruiting nowThis study tests whether adding the drug ruxolitinib to standard treatment (radiation and temozolomide) helps people with newly diagnosed glioblastoma live longer. About 190 adults will be randomly assigned to receive either the standard treatment alone or standard treatment plus…
Matched conditions: MGMT-METHYLATED GLIOBLASTOMA
Phase: PHASE2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC